Lifecare strengthens miniaturisation roadmap with new patent applications

24 Sep 2025 07:00 CEST

Bergen, Norway, 24 September 2025 -- Lifecare ASA (LIFE), a MedTech company
developing next-generation continuous glucose monitoring (CGM) technology,
announces that new patent applications have been filed in Europe and the
United States related to surface acoustic wave (SAW) sensing for osmotic
glucose measurement.

SAW sensors are tiny chips that detect extremely small surface vibrations and
are already widely used in other industries. When combined with Lifecare's
proprietary osmotic principle -- where glucose levels are reflected as
pressure changes -- SAW sensors provide an additional way to measure these
changes in very small devices.

This technology strengthens Lifecare's roadmap towards further miniaturisation
of implantable sensors. The company's first product generation is based on
proven, commercially available piezoresistive pressure sensors, ensuring size,
reliability, and manufacturability for today's needs.

Alongside Lifecare's licensed Nano Tunneling Resistor (NTR) technology, SAW
represents an alternative option for future miniaturisation -- with the
potential to improve sensitivity while supporting standardised production
methods for faster development.

The patent applications have been filed by Lifecare's academic partner Johann
Wolfgang Goethe University Frankfurt, under a framework that grants Lifecare
defined R&D rights and an option to secure commercial rights. The European
application (EP 4 619 744) is scheduled for publication in the European Patent
Bulletin on 24 September 2025.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is suitable for identifying and monitoring the occurrence of a wide
range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

656013_Lifecare strengthens miniaturisation roadmap with new patent applications.pdf